Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geert D'Haens

Showing results (91-100 of 269) with videos related to

Pageof 27
Sort By:
Gastroenterology|October 13, 2009
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's diseaseFilip Baert, Liesbeth Moortgat, Gert Van Assche, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 9, 2025
Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn's DiseaseZhigang Wang, Yannick Hoffert, Wei Zhang, et al.
Digestive Diseases and Sciences|April 3, 2024
Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's DiseaseSarah Harris, Brian G Feagan, Stephen Hanauer, et al.
Gastroenterology|August 31, 2019
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative ColitisWilliam J Sandborn, Filip Baert, Silvio Danese, et al.
Inflammatory Bowel Diseases|July 17, 2024
Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple SclerosisMiguel Regueiro, Britta Siegmund, Sara Horst, et al.
European Journal of Gastroenterology & Hepatology|February 28, 2024
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studiesGeert D'Haens, Filip Baert, Silvio Danese, et al.
Journal of Crohn'S & Colitis|September 21, 2021
Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's DiseaseWilliam J Sandborn, James D Lewis, Julian Panes, et al.
Gastroenterology|November 9, 2011
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitisWilliam J Sandborn, Gert van Assche, Walter Reinisch, et al.
Inflammatory Bowel Diseases|February 21, 2012
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel diseaseGeert D'Haens, Marc Ferrante, Severine Vermeire, et al.
Journal of Crohn'S & Colitis|December 28, 2016
Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional TherapyGeert D'Haens, Walter Reinisch, Jean-Frederic Colombel, et al.
Pageof 27

Showing results (91-100 of 269) with videos related to

Sort By:
Pageof 27
Gastroenterology|October 13, 2009
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's diseaseFilip Baert, Liesbeth Moortgat, Gert Van Assche, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 9, 2025
Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn's DiseaseZhigang Wang, Yannick Hoffert, Wei Zhang, et al.
Digestive Diseases and Sciences|April 3, 2024
Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's DiseaseSarah Harris, Brian G Feagan, Stephen Hanauer, et al.
Gastroenterology|August 31, 2019
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative ColitisWilliam J Sandborn, Filip Baert, Silvio Danese, et al.
Inflammatory Bowel Diseases|July 17, 2024
Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple SclerosisMiguel Regueiro, Britta Siegmund, Sara Horst, et al.
European Journal of Gastroenterology & Hepatology|February 28, 2024
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studiesGeert D'Haens, Filip Baert, Silvio Danese, et al.
Journal of Crohn'S & Colitis|September 21, 2021
Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's DiseaseWilliam J Sandborn, James D Lewis, Julian Panes, et al.
Gastroenterology|November 9, 2011
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitisWilliam J Sandborn, Gert van Assche, Walter Reinisch, et al.
Inflammatory Bowel Diseases|February 21, 2012
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel diseaseGeert D'Haens, Marc Ferrante, Severine Vermeire, et al.
Journal of Crohn'S & Colitis|December 28, 2016
Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional TherapyGeert D'Haens, Walter Reinisch, Jean-Frederic Colombel, et al.
Pageof 27